Business
Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules
Absorption improvements appear to continue with DehydraTECH-processed Rybelsus® vs. Rybelsus® tablets even under "fed" conditionsDehydraTECH-treated Rybelsus®
About this update from Lexaria Bioscience Corp.
[{"type":"text","content":"Absorption improvements appear to continue with DehydraTECH-processed Rybelsus® vs. Rybelsus® tablets even under \"fed\" conditionsDehydraTECH-treated Rybelsus® does absorb through a mouth-melt product format KELOWNA, BC / ACCESSWIRE / August 29, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the \"Company\" or \"Lexaria\"), a global innovator in drug delivery platforms announces that tolerability and additional pharmacokinetic (\"PK\") results from human pilot study #2, GLP-1-H24-2, (the \"Study\") have been received. Lexaria's DehydraTECH-processed Rybelsus® capsules demonstrated superior tolerability in delivering the GLP-1 drug semaglutide versus commercially available Rybelsus®.We were pleased to find that none (0) of the 9 people taking the DehydraTECH-processed Rybelsus® swallowed as a capsule experienced any adverse events whatsoever. However, of the 9 human volunteers in the Study taking the Rybelsus® tablet, 6 of them experienced mild adverse events. Five of those same 6 people experienced mild adverse events from taking the dissolvable oral mouth-melt format of DehydraTECH-processed Rybelsus®.These tolerability findings nicely build upon the those from Lexaria's previous human pilot study #1, GLP-1-H24-1, which also showed the DehydraTECH-processed Rybelsus® capsules to be generally better tolerated than the Rybelsus® tablets that demonstrated instances of moderate nausea or diarrhea.Adverse Events from Pilot Studies #1 (GLP-1-H24-1) and #2 (GLP-H24-2) Pilot Study #1(n=7)Pilot Study #2(n=9)Total (n=16)Rybelsus® Tablet4 mild3 moderate6 mild0 moderate10 mild (63%)3 moderate (19%)DehydraTECH-processed Rybelsus Capsule7 mild0 moderate0 mild0 moderate7 mild (44%)0 moderate (0%)Combined with the 7 people involved in Lexaria's first human pilot study examining DehydraTECH processing of semaglutide capsules, a total of 16 people have now been dosed with comparable DehydraTECH-processed semaglutide capsules and Rybelsus® tablets. Of those 16 people, 13 or 81%, experienced mild or moderate side effects with the Rybelsus® tablet and only 7 people, or 44%, experienced only mild side effects with the Rybelsus® that was processed with DehydraTECH and administered via capsules. Most of the side effects experienced in all cases were of a gastrointestinal nature including belching, diarrhea and nausea that are commonly a...